Open AccessrBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma
Author(s) -
Mawaribuchi Shuuji,
Haramoto Yoshikazu,
Tateno Hiroaki,
Onuma Yasuko,
Aiki Yasuhiko,
Ito Yuzuru
Publication year - 2020
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12852
Subject(s) - breast carcinoma , breast cancer , carcinoma , lectin , cancer research , induced pluripotent stem cell , biology , cancer , staining , human epidermal growth factor receptor 2 , pathology , oncology , medicine , gene , immunology , embryonic stem cell , genetics
The recombinant N‐terminal domain of BC2L‐C lectin (rBC2LCN) is useful for detecting not only human pluripotent stem cells but also some cancers. However, the cancer types and stages that can be detected by rBC2LCN remain unclear. In this study, we identified the human breast carcinoma subtypes and stages that can be detected by rBC2LCN. Compared with rBC2LCN‐negative breast carcinoma cell lines, the rBC2LCN‐positive cells expressed higher levels of human epidermal growth factor receptor 2 ( HER2 ) and epithelial marker genes. Importantly, rBC2LCN histochemical staining of human breast carcinoma tissues demonstrated the utility of rBC2LCN in detecting breast carcinoma types that express HER2 and have not spread much in the early phase of growth. We conclude that rBC2LCN may have potential as a detection probe and a drug delivery vehicle to identify and treat early‐stage HER2‐positive breast carcinoma.